Brenig Therapeutics Begins First Human Trial of BT-267 for Parkinson's Disease

Brenig Therapeutics has announced the launch of its inaugural clinical trial for BT-267, a leading LRRK2 inhibitor designed to potentially modify the course of idiopathic and LRRK2-associated Parkinson’s disease. This significant development in Brenig’s research is bolstered by a recent $65 million investment, primarily funded by New Enterprise Associates.

The clinical trial commenced in November 2024, initially involving healthy volunteers to assess the safety and tolerability of BT-267. Subsequent to this preliminary phase, the company plans to conduct proof-of-concept studies involving patients diagnosed with idiopathic Parkinson’s disease.

Preclinical research highlights BT-267’s potential as a top-tier LRRK2 inhibitor, demonstrating an excellent safety profile. These studies showed minimal to no detectable changes in lung or kidney morphology at the highest tested doses during GLP toxicology evaluations. Additionally, BT-267 exhibited outstanding pharmacokinetic properties, notably a high cerebrospinal fluid (CSF) to plasma unbound ratio.

BT-267’s development benefits from advanced computer-aided drug design, artificial intelligence and machine learning-driven computational pharmacology, biomarker models, and the structural biology expertise of its partner, Expert Systems Accelerator. Brenig’s sophisticated approach to predictive biomarkers may help position BT-267 as a promising disease-modifying treatment for Parkinson’s, including idiopathic forms that do not have identifiable genetic causes.

Brenig Therapeutics is committed to pioneering innovative therapies for neurodegenerative diseases. Through cutting-edge science and a patient-centric approach, Brenig endeavors to offer transformative solutions that address the fundamental causes of these debilitating disorders.